Nearly 60 years after tardive dyskinesia (TD) was recognized as a disease, patients may soon have a drug approved to treat their involuntary movements.
More than two years after the Jumpstart Our Business Startups (JOBS) Act was signed into law, Title III of the act, which allows for equity-based crowdfunding from non-accredited investors, still hasn't been implemented by the SEC.
Claravant Analytics LLC is looking to become the drug industry's version of a credit rating agency, doing independent reviews of a drug's likelihood of gaining regulatory approval.
The attention deficit hyperactivity disorder (ADHD) market is $10 billion strong, but grabbing a piece of the pie with so many drugs already on the market, including some generics, requires differentiation.
SAN DIEGO – The Russian government is making a push to diversify its economy away from oil and gas into technology-based industries, including biomedical research.
SAN DIEGO – At the BIO International Convention, BIO Ventures for Global Health (BVGH) announced a partnership with the National Universities Commission (NUC) of Nigeria to place Nigerian academics at pharmaceutical and biotech companies.
In a Thursday session at BIO 2014 next week, attendees will get a lesson from a panel of experts on how to get a piece of the government funding available for companies developing medical countermeasures (MCMs).
In a Thursday session at BIO 2014 next week, attendees will get a lesson from a panel of experts on how to get a piece of the government funding available for companies developing medical countermeasures (MCMs).
